UY26874A1 - Compuestos heterocíclicos como ligandos de los receptores gaba - Google Patents

Compuestos heterocíclicos como ligandos de los receptores gaba

Info

Publication number
UY26874A1
UY26874A1 UY26874A UY26874A UY26874A1 UY 26874 A1 UY26874 A1 UY 26874A1 UY 26874 A UY26874 A UY 26874A UY 26874 A UY26874 A UY 26874A UY 26874 A1 UY26874 A1 UY 26874A1
Authority
UY
Uruguay
Prior art keywords
gaba
heterocyclic compounds
agonists
receivers
links
Prior art date
Application number
UY26874A
Other languages
English (en)
Inventor
George Maynard
Lawrence Albert Vincent
Daniel Yohannes
Jun Yuan
Linghong Xie
Kungae Lee
Manuka Ghosh
George Luke
Xiaojun Liu
Art Nagel
Kevin Currie
Zhe-Qing Wang
Original Assignee
Pfizer Inc Y Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc Y Neurogen Corp filed Critical Pfizer Inc Y Neurogen Corp
Publication of UY26874A1 publication Critical patent/UY26874A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Lo que se divulga en el presente son compuestos heterocíclicos de la fórmula y sales farmacéuticamente aceptables de la misma cuya característica es que las variables A, V, Y, J, E, X, T, G, Q, W, Z, b, n y m se definen en el presente. Estos compuestos son agonistas, antagonistas o agonistas invertidos altamente selectivos para los receptores cerebrales GABA o profármacos de agonistas, antagonistas o agonistas invertidos para los receptores cerebrales GABA.
UY26874A 2000-08-07 2001-08-07 Compuestos heterocíclicos como ligandos de los receptores gaba UY26874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22366900P 2000-08-07 2000-08-07

Publications (1)

Publication Number Publication Date
UY26874A1 true UY26874A1 (es) 2002-03-22

Family

ID=22837525

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26874A UY26874A1 (es) 2000-08-07 2001-08-07 Compuestos heterocíclicos como ligandos de los receptores gaba

Country Status (18)

Country Link
US (2) US6653471B2 (es)
EP (1) EP1325006A2 (es)
JP (1) JP2004505942A (es)
KR (1) KR20030036678A (es)
CN (1) CN1468241A (es)
AU (1) AU2001285401A1 (es)
BR (1) BR0113120A (es)
CA (1) CA2420967A1 (es)
CO (1) CO5310576A1 (es)
EC (1) ECSP014130A (es)
HN (1) HN2002000193A (es)
IL (1) IL154310A0 (es)
MX (1) MXPA03001186A (es)
PA (1) PA8524601A1 (es)
PE (1) PE20020275A1 (es)
TN (1) TNSN01122A1 (es)
UY (1) UY26874A1 (es)
WO (1) WO2002012442A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
JP2005525333A (ja) 2002-02-07 2005-08-25 ニューロジェン コーポレイション 置換縮合ピラゾールカルボン酸アリールアミド及び関連化合物
FR2857363B1 (fr) * 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
DK1848430T3 (da) * 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US8583926B1 (en) 2005-09-19 2013-11-12 Jpmorgan Chase Bank, N.A. System and method for anti-phishing authentication
WO2007053352A2 (en) * 2005-10-28 2007-05-10 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US20070099911A1 (en) * 2005-10-28 2007-05-03 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
EP1968941A1 (en) * 2005-12-29 2008-09-17 Novartis AG Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
CA2650954C (en) 2006-05-10 2014-02-11 Novartis Ag Bicyclic derivatives as cetp inhibitors
US20090181929A1 (en) * 2006-05-11 2009-07-16 Kazuhide Konishi Organic compounds
KR20090080523A (ko) * 2006-11-15 2009-07-24 노파르티스 아게 Ｃετρ 억제제로서의 헤테로시클릭 유도체
EP2190850A4 (en) * 2007-07-03 2011-03-09 Univ British Columbia DELTAF508 CFTR DELTAF508 DELTAFLECTIVE TRANSPORTATION MOLECULES
ME02340B (me) 2008-06-10 2017-02-20 Abbvie Inc Triciklična jedinjenja
CN102414203B (zh) * 2009-05-07 2014-11-26 弗·哈夫曼-拉罗切有限公司 用作gaba调节剂的异*唑-吡啶衍生物
AU2010326030A1 (en) 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
UY33071A (es) 2009-12-01 2011-05-31 Abbott Lab Nuevos compuestos tricíclicos
US8461328B2 (en) * 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2012229952A1 (en) * 2011-03-15 2013-04-18 Abbvie Inc. Nuclear hormone receptor modulators
EP3718547A1 (en) 2011-10-03 2020-10-07 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
BR112014030812B1 (pt) 2012-06-13 2022-11-08 Incyte Holdings Corporation Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
KR101663864B1 (ko) * 2013-04-19 2016-10-07 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 약학조성물
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2015125858A1 (ja) * 2014-02-24 2015-08-27 日本曹達株式会社 ヘテロアリール化合物およびその用途
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
MX2018004605A (es) 2015-10-16 2018-11-29 Abbvie Inc Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
US11891377B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206415A (en) 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5344626A (en) * 1992-06-26 1994-09-06 Minnesota Mining And Manufacturing Company Dual impregnated activated carbon
US5723462A (en) 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
GB9708945D0 (en) * 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
DE69807074T2 (de) * 1997-05-08 2003-04-03 Merck Sharp & Dohme Substituierte 1,2,4-triazolo[3,4,-a]phthalazin-derivate als gaba-alpha 5-liganden
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
WO1999029319A2 (en) 1997-12-09 1999-06-17 Neurosearch A/S Chemical compounds for use as anxiolytic agents and a method for the identification of anxiolytic compounds
AU2879799A (en) * 1998-02-26 1999-09-15 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
WO1999043682A1 (en) * 1998-02-26 1999-09-02 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives, their preparation and their use as (ant-)agonists for gaba (a) brain receptors

Also Published As

Publication number Publication date
US6949562B2 (en) 2005-09-27
MXPA03001186A (es) 2004-04-20
JP2004505942A (ja) 2004-02-26
PA8524601A1 (es) 2003-09-05
US6653471B2 (en) 2003-11-25
CN1468241A (zh) 2004-01-14
PE20020275A1 (es) 2002-04-09
TNSN01122A1 (fr) 2005-11-10
ECSP014130A (es) 2002-03-25
WO2002012442A3 (en) 2003-05-01
BR0113120A (pt) 2004-06-22
US20040110778A1 (en) 2004-06-10
HN2002000193A (es) 2002-11-05
US20030105081A1 (en) 2003-06-05
CO5310576A1 (es) 2003-08-29
CA2420967A1 (en) 2002-02-14
WO2002012442A2 (en) 2002-02-14
KR20030036678A (ko) 2003-05-09
AU2001285401A1 (en) 2002-02-18
IL154310A0 (en) 2003-09-17
EP1325006A2 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
UY26874A1 (es) Compuestos heterocíclicos como ligandos de los receptores gaba
UY26872A1 (es) Derivados de la 4- fenil piridina
UY27918A1 (es) Derivados de benzodioxol
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
UY26276A1 (es) 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164
HN2004000544A (es) Nuevos derivados de quinolinas
PA8600501A1 (es) Ligandos de receptor cannabinoide y usos de los mismos
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
CR7932A (es) Pirazolo (1,5-a) (1,3,5) derivados de triazina como ligandos de receptor de cannabinoides
ECSP055684A (es) Antagonistas del receptor opiode
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
CR8333A (es) Derivados biciclicos [3.1.0 ] como inhibidores del transportador de glicina
UY27551A1 (es) Derivados de benzotiazol
CL2003002770A1 (es) Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides
UY26729A1 (es) Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos
ECSP034917A (es) Nuevos derivados de acido sulfonico
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
PA8589801A1 (es) Aminoalcoxiindoles
CU24550B1 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos
EA200700364A1 (ru) Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda
CR9436A (es) Derivados de aril 1,4-pirazina sustituidos
PA8486701A1 (es) Antagonistas de 5ht1 para terapia antidepresiva
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
ES2107505T3 (es) Derivados de bencimidazol, un metodo para producirlo, fungicidas agricolas y horticolas que lo contienen como ingrediente activo y compuestos intermedios en su preparacion.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140807